Iseganan IntraBiotics Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 225-228

  Toney, Jeffrey H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IB 367; ISEGANAN; MEMBRANE LIPID; PLACEBO; PNU 196443; PROTEGRIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ESCHERICHIA COLI; ESOPHAGITIS; GEL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOUTH FLORA; MOUTHWASH; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; STOMATITIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TASTE DISORDER; TOXICITY TESTING;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MOUTH MUCOSA; PEPTIDES; PROTEINS; RANDOMIZED CONTROLLED TRIALS; STOMATITIS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0036225207     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Using host defenses to fight infectious diseases
2. IntraBiotics Pharmaceuticals begins phase I safety testing of IB-367, a novel treatment for mucositis in cancer patients
3. IntraBiotics teams with Pharmacia & Upjohn to develop novel antimicrobial, IB-367
4. IntraBiotics announces results of phase I trial of protegrin IB-367 for the treatment of oral mucositis
5. IntraBiotics receives milestone payment from collaboration with Pharmacia & Upjohn
6. Topical administration of IB-367, a novel antimicrobial peptide, reduces the severity of oral mucositis, in 5-FU-treated hamsters
7. Intrabiotics begins phase I clinical trial of protegrin IB-367 aerosol for the treatment of respiratory infections
8. IntraBiotics reacquires global rights to protegrin IB-367
9. IntraBiotics receives patent on prointegrin IB-367
10. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy
11. IntraBiotics receives patent on methods for the prevention and treatment of oral mucositis
12. CHI's Second Annual Protein Discovery Technologies Conference, New Methods and Applications in Therapeutic Development, Boston, MA, USA
13. Protegrin: Background
14. IntraBiotics announces phase III study start for Protegrin IB-367 rinse
15. Interaction of the protegrin analog IB-367 with cell surfaces and membranes
16. Structure-function analysis of IB-367, a broad-spectrum protegrin antibiotic
17. IntraBiotics
18. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis
19. 100th American Society for Microbiology annual meeting
20. Protegrins: New antibiotics of mammalian origin
21. Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues
22. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters
23. IB 367
24. IntraBiotics begins phase IIa clinical trial of protegrin IB-367 rinse for ventilator-associated pneumonia
25. IntraBiotics completes patient enrollment in phase III study of protegrin IB-367 rinse; Study power reduced due to incorrect administration of some clinical supplies; FDA grants fast-track status for protegrin IB-367 rinse
26. Phase I data on protegrin IB-367 rinse for ventilator-associated pneumonia reported at society for critical care medicine symposium
27. Final results from phase III trial of protegrin IB-367 rinse reported at Annual Meeting of ASCO
28. A phase IIa safety and microbial kinetic study of iseganan (IB-367) oral solution in intubated patients receiving mechanical ventilation
29. Intrabiotics reports third quarter financial results
30. IntraBiotics announces start of phase III trial of iseganan for oral mucositis
31. IntraBiotics completes patient enrollment in phase III study of iseganan to reduce oral mucositis
32. Identification of Proteus mirabilis mutants with increased sensitivity to antimicrobial peptides
33. Intrabiotics presents iseganan phase IIa data at ESICM